Study Title
An Observational Evaluation in Multiple Myeloma (PREAMBLE)
Purpose
To better understand the clinical effectiveness of therapies used in treating relapsed/refractory multiple myeloma (MM) in the real-world clinical practice.
Eligibility
Diagnosed with relapse or refractory Multiple Myeloma (MM)
Received at least one prior treatment of therapy for MM
Age of 18 years or older
Have documented progression from most recent line of therapy
Not currently participating in a clinical trial for MM
Study Process
Subjects will be followed every 3 months while participating.
Trial Details
Investigator:
Michael Moore, M.D.
IRB:
Quorum
IRB Number:
Trial Type:
Drug
Sponsor:
Bistrol Myers Squibb
Contact Information:
Hematology Oncology Associates
(318) 212-8620
http://cancer.wkhs.com